Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study.
Abramson JS, Solomon SR, Arnason J, Johnston PB, Glass B, Bachanova V, Ibrahimi S, Mielke S, Mutsaers P, Hernandez-Ilizaliturri F, Izutsu K, Morschhauser F, Lunning M, Crotta A, Montheard S, Previtali A, Ogasawara K, Kamdar M.
Abramson JS, et al. Among authors: previtali a.
Blood. 2023 Apr 6;141(14):1675-1684. doi: 10.1182/blood.2022018730.
Blood. 2023.
PMID: 36542826
Free PMC article.
Clinical Trial.